Cholesterol Drug Showing Promise Against COVID-19 Fails in Human Trials; Unable to Reduce Severe Symptoms or Death in Patients: Study
A new international multi-institutional study led by scientists from Penn Medicine has found that fenofibrate was unable to reduce the severity of disease or prevent adverse outcomes such as deaths in COVID-19 patients.